PATENT CLAIM ANALYSIS

Application Number: 15918195
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "210210"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Claim (Index 12):
The compound of  claim 1 , wherein:\n ring B is heteroaryl or bridged heterocycle, each containing carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, NH, O, and S(O) p , and each substituted with 1-3 R 5 ; R 2  is selected from the group consisting of: H, F, CN, \u2014CO(C 1-4  alkyl), OH, \u2014O(C 1-4  alkyl), \u2014OCHF 2 , \u2014CHF 2 , \u2014CF 3 , triazole, and tetrazole, wherein said triazole and tetrazole are substituted with 0-2 R 2a ; and R 5 , at each occurrence, is selected from the group consisting of: H, \u2550O, halo, C 1-4  alkyl, OH, CN, NH 2 , \u2014N(C 1-4  alkyl) 2 , C 1-4  alkoxy, \u2014CO 2 H, \u2014CO 2 (C 1-4  alkyl), \u2014CONH 2 , \u2014CONR 9 (C 1-4  alkyl), \u2014CON(C 1-4  alkyl) 2 , R 8 , and \u2014COR 8 .

Metadata:
- Claim Count in Document: 15.0
- Percentile: 90.0
- Lexical Diversity: 1.17949
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14117513', '15361589', '14617979', '14886415', '14350411']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8630488614995204
- 35 USC 102 Novelty (BERT): 0.6565781552963182
- Combined Prediction Score: 0.8424017908792002
- Mean Citation Score: 542.883702
- Max Citation Score: 635.02765
- Similarity Product: 626.8552139418097

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test